Research ArticleArticle

Bone Mineral Density Change in Systemic Lupus Erythematosus: A 5-year Followup Study

Tracy Y. Zhu, James F. Griffith, Sze-Ki Au, Xiao-Lin Tang, Anthony W. Kwok, Ping-Chung Leung, Edmund K. Li and Lai-Shan Tam
The Journal of Rheumatology October 2014, 41 (10) 1990-1997; DOI: https://doi.org/10.3899/jrheum.131190

REFERENCES

  1. 1.↵
    1. Bultink IE
    . Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 2012;64:2–8.
    OpenUrlCrossRef
  2. 2.↵
    1. Bultink IE,
    2. Lems WF,
    3. Kostense PJ,
    4. Dijkmans BA,
    5. Voskuyl AE
    . Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:2044–50.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Li EK,
    2. Tam LS,
    3. Griffith JF,
    4. Zhu TY,
    5. Li TK,
    6. Li M,
    7. et al.
    High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol 2009;36:1646–52.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Ramsey-Goldman R,
    2. Dunn JE,
    3. Huang CF,
    4. Dunlop D,
    5. Rairie JE,
    6. Fitzgerald S,
    7. et al.
    Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999;42:882–90.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Yee CS,
    2. Crabtree N,
    3. Skan J,
    4. Amft N,
    5. Bowman S,
    6. Situnayake D,
    7. et al.
    Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005;64:111–3.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Becker A,
    2. Fischer R,
    3. Scherbaum WA,
    4. Schneider M
    . Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus 2001;10:809–14.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Almehed K,
    2. Forsblad d’Elia H,
    3. Kvist G,
    4. Ohlsson C,
    5. Carlsten H
    . Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology 2007;46:1185–90.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Lakshminarayanan S,
    2. Walsh S,
    3. Mohanraj M,
    4. Rothfield N
    . Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001;28:102–8.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Mendoza-Pinto C,
    2. Garcia-Carrasco M,
    3. Sandoval-Cruz H,
    4. Escarcega RO,
    5. Jimenez-Hernandez M,
    6. Etchegaray-Morales I,
    7. et al.
    Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol 2009;28:65–70.
    OpenUrlPubMed
  10. 10.↵
    1. Boyanov M,
    2. Robeva R,
    3. Popivanov P
    . Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol 2003;22:318–23.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Kipen Y,
    2. Briganti E,
    3. Strauss B,
    4. Will R,
    5. Littlejohn G,
    6. Morand E
    . Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol 1999;26:310–7.
    OpenUrlPubMed
  12. 12.↵
    1. Pons F,
    2. Peris P,
    3. Guanabens N,
    4. Font J,
    5. Huguet M,
    6. Espinosa G,
    7. et al.
    The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol 1995;34:742–6.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Jacobs J,
    2. Korswagen LA,
    3. Schilder AM,
    4. van Tuyl LH,
    5. Dijkmans BA,
    6. Lems WF,
    7. et al.
    Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int 2013;24:1827–33.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Jardinet D,
    2. Lefebvre C,
    3. Depresseux G,
    4. Lambert M,
    5. Devogelaer JP,
    6. Houssiau FA
    . Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology 2000;39:389–92.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Hansen M,
    2. Halberg P,
    3. Kollerup G,
    4. Pedersen-Zbinden B,
    5. Horslev-Petersen K,
    6. Hyldstrup L,
    7. et al.
    Bone metabolism in patients with systemic lupus erythematosus. Effect of disease activity and glucocorticoid treatment. Scand J Rheumatol 1998;27:197–206.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Hochberg MC
    . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Buyon JP,
    2. Petri MA,
    3. Kim MY,
    4. Kalunian KC,
    5. Grossman J,
    6. Hahn BH,
    7. et al.
    The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;12 Pt 1:953–62.
    OpenUrl
  18. 18.↵
    1. Zhu TY,
    2. Tam LS,
    3. Lee VW,
    4. Lee KK,
    5. Li EK
    . The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009;61:1159–67.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C,
    4. Fortin P,
    5. Liang M,
    6. Urowitz M,
    7. et al.
    The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Gluer CC,
    2. Blake G,
    3. Lu Y,
    4. Blunt BA,
    5. Jergas M,
    6. Genant HK
    . Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 1995;5:262–70.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Lynn HS,
    2. Lau EM,
    3. Au B,
    4. Leung PC
    . Bone mineral density reference norms for Hong Kong Chinese. Osteoporos Int 2005;16:1663–8.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Liberman UA,
    2. Weiss SR,
    3. Broll J,
    4. Minne HW,
    5. Quan H,
    6. Bell NH,
    7. et al.
    Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437–43.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Orwoll E,
    2. Ettinger M,
    3. Weiss S,
    4. Miller P,
    5. Kendler D,
    6. Graham J,
    7. et al.
    Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604–10.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. McClung MR,
    2. Geusens P,
    3. Miller PD,
    4. Zippel H,
    5. Bensen WG,
    6. Roux C,
    7. et al.
    Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333–40.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Chesnut IC,
    2. Skag A,
    3. Christiansen C,
    4. Recker R,
    5. Stakkestad JA,
    6. Hoiseth A,
    7. et al.
    Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Teichmann J,
    2. Lange U,
    3. Stracke H,
    4. Federlin K,
    5. Bretzel RG
    . Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int 1999;18:137–40.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Weinstein RS
    . Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011;365:62–70.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Grossman JM,
    2. Gordon R,
    3. Ranganath VK,
    4. Deal C,
    5. Caplan L,
    6. Chen W,
    7. et al.
    American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515–26.
    OpenUrlCrossRef
  29. 29.↵
    1. Van Staa TP,
    2. Leufkens HG,
    3. Abenhaim L,
    4. Zhang B,
    5. Cooper C
    . Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993–1000.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Ho SC,
    2. Chan SG,
    3. Yip YB,
    4. Chan CS,
    5. Woo JL,
    6. Sham A
    . Change in bone mineral density and its determinants in pre- and perimenopausal Chinese women: the Hong Kong Perimenopausal Women Osteoporosis Study. Osteoporos Int 2008;19:1785–96.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

SYSTEMIC LUPUS ERYTHEMATOSUS
BONE MINERAL DENSITY
ORGAN DAMAGE
GLUCOCORTICOIDS

Keywords